New Post has been published on Stock Markets Daily
New Post has been published on http://www.stockmarketsdaily.com/analysts-strong-buy-on-athersys-nasdaqathx/11620/
Analysts Strong Buy on Athersys (NASDAQ:ATHX)
(adsbygoogle = window.adsbygoogle || []).push();
Athersys, Inc. (NASDAQ:ATHX) has been on a steep run up in price since late 2015. So are analysts still as positive on it even with the current run up in price? We look to see. [Trend Analysis]
Analysis
Athersys, Inc. (NASDAQ:ATHX) last traded at $2.82 after moving down -1.40% for the trading day. The company last released their quarterly earnings results on March 12 for the period ended Dec-14. The company reported earnings of -$0.08 against a Zack’s research estimate of -$0.09. This represents a -11.11% surprise on the expected result.
The current average broker recommendation for Athersys, Inc., according to Zack’s research, is 1.00, based on 3 broker ratings. With 1 being a strong buy and 5 being a strong sell, this means that on a consensus basis, analysts currently see Athersys, Inc. as a strong buy. The 12 month target consensus price estimate among these analysts for Athersys, Inc. is currently at $3.84.
Out of the 3 broker recommendations for ATHX, 3 recommend it as a strong buy, 0 as a buy, 0 as a hold 0 as a sell and 0 as a strong sell.
For the current quarter, the consensus analyst estimate for Athersys, Inc. (NASDAQ:ATHX) is N/A, with analysts expecting year on year growth for the company of N/A
About Athersys, Inc. (NASDAQ:ATHX)
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company’s lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived “off the shelf” stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.